Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compared With Fosaprepitant Dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of HR20013 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy

Next Previous
Trial Profile

Compared With Fosaprepitant Dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of HR20013 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosrolapitant/palonosetron (Primary) ; Dexamethasone; Fosaprepitant; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Acronyms PROFIT
  • Sponsors Fujian Shengdi Pharmaceutical

Most Recent Events

  • 30 May 2025 According to a Fujian Shengdi Pharmaceutical Co media release, full text results has been published in the Journal of Clinical Oncology (JCO, IF=42.1)
  • 30 May 2025 According to a Fujian Shengdi Pharmaceutical Co media release, company received a notice from State Medical Products Administration to approve the marketing of the company's Class 1 innovative drug phosphoropitapitan palonosetron for injection (trade name:retanin).
  • 12 Sep 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top